Pulmonary artery hypertension
Conditions
Interventions
Trial group:Targeted drug therapy(Ambrisentan 10mg once daily) and cognitive behavioral therapy once aweek
Control group:Targeted drug therapy(Ambrisentan 10mg once daily)
Sponsors
Handan First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Clearly diagnosed with PH (mean pulmonary arterial pressure >=25 mm Hg measured by right heart catheterization at sea level at rest); 2. Expected survival time >=6 months; 3. No speech, psychiatric, or cognitive impairments; 4. WHO functional class I-III; 5. Willing to receive education and adhere to a regular lifestyle during the trial; 6. Informed and consented.
Exclusion criteria
Exclusion criteria: 1.History of psychiatric illness; 2. Intellectual disability, motor disorders, or disturbance of consciousness, etc.; 3.Se hepatic or renal insufficiency; 4. Patients with malignant diseases; 5.Those who drop out of treatment halfway or lose follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anxiety level: the HAM-A scores were measured at baseline and 3 months after the intervention.;Depressive level: the HAMD rating was applied before and 3 months after the intervention.;Sleep quality: the Pittsburgh Sleep Quality Index (PSQI) was used to score before and 3 months after the intervention;Quality of life: the quality of life was evaluated by the 36-Item Short-Form Health Survey (SF-36) before 3 months after the intervention.;WHO functional grading;6-minute walk test;Plasma NT-proBNP;Estimate tricuspid annular plane systolic excursion (TAPSE), systolic pulmonary artery pressure and right vent ejection fraction by echocardiography.; | — |
Countries
China
Contacts
Public ContactWang Xiaoli
Handan First Hospital
Outcome results
None listed